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Background: Platelet-rich plasma (PRP) preparations are a common treatment in osteoarthritis (OA) and inflammatory
synovitis. However, there is ambiguity regarding the ideal concentration of leukocytes and platelets in these
preparations necessary to induce an adequate anti-inflammatory and anabolic response in joint tissues, such
as the synovial membrane. This research aimed to study, in normal synovial membrane explants (SME) challenged
with lipopolysaccharide (LPS), the temporal effects (at 48 and 96h) of leukocyte- and platelet-rich gel (L-PRG) and
pure platelet-rich gel (P-PRG) supernatants on the production and degradation of platelet associated growth
factors (GF) (platelet derived GF isoform BB (PDGF-BB) and transforming growth factor beta-1 (TGF-β1)), pro-inflammatory
(tumour necrosis factor alpha (TNF-α)) and anti-inflammatory cytokines (interleukin 4 (IL-4) and IL-1 receptor antagonists
(IL-1ra)) and hyaluronan (HA).
Methods: Synovial membrane explants (SMEs) from 6 horses were challenged with LPS and cultured for 96h with L-PRG
and P-PRG supernatants at concentrations of 25 and 50 %, respectively. The SME culture medium was changed every
48h and used for determination by ELISA of PDGF-BB, TGF-β1, TNF-α, IL-4, IL-1ra and HA. These molecules were
also determined in synovial fluid from the horses.
Results: Both the 25 and 50 % PRG supernatants produced a molecular profile in the culture media unlike that of the
SME challenged with LPS only. They presented GF, cytokine and HA concentrations very near to the concentrations of
these molecules in normal synovial fluid when compared with the SME control groups (either with LPS or without LPS).
However, in comparison with the rest of the SME treated groups, the 25 % L-PRG produced the most IL-1ra, and the
50 % P-PRG induced the sustained production of IL-4 and HA.
Conclusions: These in vitro findings suggest that anabolic and anti-inflammatory joint responses depend on the
leukocyte and platelet concentration of the PRP preparation and on the volume of this substance injected. Moreover,
it is possible, that leukoreduced PRP preparations are more effective for the medical treatment of patients with OA
and inflammatory synovitis.Background
Synovitis is a common clinical and pathological alter-
ation observed in people with OA [1]. The clinical con-
dition of osteoarthritic patients may be more severe
when synovitis is present [2]. Osteoarthritic patients
who present with mild to severe synovitis are likely to be* Correspondence: carmona@ucaldas.edu.co
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goal of OA treatment is to establish an early diagnosis,
to correct the initiating causes and to commence either
intra-articular, systemic or both pharmacological treat-
ments in order to diminish pain, avoid further joint
damage, and facilitate the recovery of normal joint
functions [1, 3].
Platelet-rich plasma (PRP) has emerged as an important
‘regenerative’ therapy in human [4–7] and animal patients
[8–10] with joint disease. Several in vitro [11–15], animalle distributed under the terms of the Creative Commons Attribution License
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PRP in OA [19]. However, the lab protocols used for
both small-scale PRP preparations and larger com-
mercial PRP preparations can yield end products
with different cellular and protein (GF) and cytokine
concentrations [20]. Due to such variations, these prepa-
rations yield variable results when used under clinical
conditions [5, 14, 21–23].
In general, PRP used for intra-articular injection is
classified into two groups [23]: leukoconcentrated PRP
(L-PRP) and leukoreduced PRP (also termed pure PRP
(P-PRP)). L-PRP preparations show both increased plate-
let (PLT) (three-five-fold or more) and leukocyte (WBC)
(threefold to fivefold or more) counts with respect to
basal cell counts in whole blood. P-PRP products exhibit
PLT counts ranging from physiologically low to twofold
and WBC counts from negligible to twofold WBC with
respect to basal cell counts in whole blood [22]. More-
over, when both PRP preparations are activated with
either calcium salts or thrombin, they are transformed in
a platelet-rich gel (PRG) from L-PRP to L-PRG and from
P-PRP to P-PRG [23].
Recent in vitro evidence suggests that P-PRP/P-PRG
could be more suitable for tendon [24, 25] and joint
treatment [11, 14, 26] than L-PRP/L-PRG because the
lower PLT and WBC concentrations in these prepara-
tions induce less tissue catabolism/inflammation and
more tissue anabolism than do PLT- and WBC-rich
preparations [11, 14, 26]. We compare the temporal
effects (at 48 and 96h) of two concentrations (25 and
50 %) of L-PRG and P-PRG supernatants with normal
synovial membrane explants (SME) challenged with lipo-
polysaccharide (LPS). For comparison purposes, we
describe the production and degradation of platelet-
associated GF (platelet-derived GF isoform BB (PDGF-BB)
and transforming GF beta-1 (TGF-β1)), pro-inflammatory
(tumour necrosis factor alpha (TNF-α)) and anti-
inflammatory cytokines (interleukin (IL) 4 (IL-4), and
IL-1 receptor antagonist (IL-1ra)), and hyaluronan (HA)
production. Further, we perform a correlation analysis
between the variables studied.
There are conflictive results regarding which PRP
preparation is ideal for the treatment of OA [27].
Thus, this research is designed to study the in vitro
response of LPS-challenged SME to several PRP
preparations. We investigate the hypothesis that both
platelet gel supernatants at different concentrations
should produce different growth factor, cytokine and
HA concentrations with respect to normal synovial
membrane explants and those cultured with LPS. We
also explore whether the 50 % P-PRG supernatant
has a better anti-inflammatory/anabolic release pro-
file than other platelet preparations do in SME chal-
lenged with LPS.Methods
This study was approved by the committee on animal
experimentation of the Universidad de Caldas, Manizales,
Colombia.
Samples
Synovial membrane samples from the dorsal metacarpo-
phalangeal joints from 6 horses, 4 to 9 years of age, were
included in this study. The samples were taken from
horses that were free from musculoskeletal disease and
euthanized by a pentobarbital intravenous overdose for
other medical reasons. All metacarpophalangeal joints
were radiographed and macroscopically evaluated to
exclude horses with OA-associated joint changes. In
addition, 2 mL of synovial fluid were obtained from
each joint in order to determine the actual concen-
trations of PDGF-BB, TGF-β1, TNF-α, IL-4, IL-1ra
and HA.
Platelet concentrates (L-PRP and P-PRP) preparation
Venous blood from 1 clinically healthy 11-year-old mare
was used in order to avoid great variability in the GF,
cytokine and HA concentrations in the PRG superna-
tants used in the experiments. Platelet concentrates were
obtained through a manual double centrifugation tube
method [28], that was previously validated and used
clinically in horses with OA [8]. Blood was drawn from
jugular venipuncture and immediately deposited in 4.5 mL
tubes with sodium citrate solution (BD Vacutainer®, Becton
Drive, Franklin Lakes, NJ, USA). After centrifugation at
120 g for five minutes, the first 50 % of the top supernatant
plasma fraction, adjacent to the buffy coat, was collected.
This fraction was centrifuged at 240 g for five minutes, and
then the bottom fourth of the fraction was collected [29].
This fraction was considered as L-PRP. The upper plasma
fraction was considered as P-PRP (Fig. 1). Whole blood
and both PRP preparations were analysed for PLT,
WBC and red blood cell (RBC) concentration using an
impedance-based haematology device (Celltac-α MEK
6450, Nihon Kodhen, Japan).
Both PRP preparations were activated with calcium glu-
conate (Ropsohn Therapeutics Ltda®, Bogotá, Colombia)
(ratio 1:10) and kept in incubation at 37 °C for 1h until
clot retraction occurred. Fresh L-PRG and P-PRG su-
pernatants were used every time culture media were
changed. Aliquots of both PRG supernatants obtained
at every time point were frozen at -86 °C for later
quantification of PDGF-BB, TGF-β1, TNF-α, IL-4, IL-1ra
and HA.
Synovial membrane explants culture and LPS challenge
Synovial membrane samples were obtained aseptically,
and circular 4 mm diameter explants were obtained
using a disposable biopsy punch (KAI Medical, Solingen,
Fig. 1 Schematic workflow of the experiments of the study
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and washed in phosphate-buffered saline. A total of 30
SME were obtained from each horse.
SME were stabilized in Dulbecco’s Modified Eagle
Medium (DMEM) (high glucose, 4500 mg/L) with L-
glutamine and sodium bicarbonate and free of sodium
pyruvate (DMEM, Lonza Group Ltd, Basel, Switzerland)
and supplemented with streptomycin (100 μg/mL) and
penicillin (100 μg /mL) without the addition of serum.
Cultures were incubated in a 5 % CO2 and water satu-
rated atmosphere for 24h and then replaced with fresh
culture media. At this time point, part of each tissue
sample was challenged with 100 ng/mL of LPS (Sigma-
Aldrich, St Louis, MO, USA) to induce inflammatory/
catabolic damage of the SME [30].
Study design
The design of the study included the evaluation of 6
experimental groups, as follows: 2 SME control groups
(1 with LPS added and 1 without LPS) without addition
of any PRG supernatant and 4 SME groups cultured
with L-PRG and P-PRG supernatants at 2 different con-
centrations (25 and 50 %).After 1h of incubation, L-PRG and P-PRG superna-
tants were added in order to obtain concentrations at 25
and 50 %. All SME groups were cultured at 48h, after
which the culture media changed and replaced with
fresh culture media and fresh PRG supernatants. The
SME groups were then incubated for an additional 48h.
Culture media obtained at 48 and 96h were aliquoted
and frozen at -86 °C for later determination of PDGF-
BB, TGF-β1, TNF-α, IL-4, IL-1ra and HA. The schematic
diagram presented is in Fig. 1 summarizes the study’s
design and methodology.
ELISA analysis
Synovial fluid, L-PRG and P-PRG supernatants, and cul-
ture media alone or with PRG supernatants obtained at
1, 48, 49 and 96h were used to determine the concentra-
tion of PDGF-BB, TGF-β1, TNF-α, IL-4, IL-1ra and HA
via ELISA by duplicate (Fig. 2). All proteins and HA
were assayed using commercial ELISA development kits
from R&D Systems (Minneapolis, MN, USA). PDGF-
BB (Human PDGF-BB DuoSet, DY220) and TGF-β1
(Human TGF-β1 DuoSet, DY240E) were determined
using human antibodies because there is a high homology
Fig. 2 TGF-β1 concentrations obtained in culture media of the synovial membrane explant groups at 48 (a) and 96 h (b). a-b Lowercase letters
denote significant (p < 0.01) differences between groups in the same column by Tukey test. a Significantly different with a: P-PRG 50 % + LPS.
b: L-PRG 50 %+ LPS and P-PRG 50 % + LPS. c: P-PRG 25 % + LPS. b Significantly different with a: P-PRG 50 % + LPS. B) b: L-PRG 50 % + LPS and P-PRG
50 % + LPS. f: L-PRG 50 % + LPS. c: P-PRG 50 % + LPS. d: P-PRG 25 % + LPS. *Denote significant differences (p < 0.01) between the same variable at 1 h
and 48 h and at 49 h and 96 by t-paired test. Data are presented as means (mean standard errors [m.s.e])
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Furthermore, these kits have been used for the same
purposes in other equine PRP studies [28]. TNF-α
(Equine TNF-alpha DuoSet, DY1814), IL-4 (Equine
IL-4 DuoSet, DY1809) and IL-1ra (Equine IL-1ra/IL-
1F3 DuoSet, DY1814) were assayed with equine-specific
antibodies, and HA (Hyaluronan, DuoSet, DY3614) was
determined using a multispecies detection ELISA kit.
The standards provided for each ELISA kit were used
in preparing each standard curve according to the man-
ufacturers’ instructions. Readings were performed at
450 nm.
Statistical and data analysis
The statistical analysis was performed with the software
SPSS 19.0 (IBM, Chicago, IL, USA). The Shapiro–Wilk
test was used to assess the fit of the data set to a normal
distribution (goodness of fit). Both PLT and WBC counts
in whole blood and both PRP presented a normal distribu-
tion (p > 0.05). PDGF-BB, TGF-β1, TNF-α, IL-4, IL-1ra and
HA concentrations were normalized using logarithm (Y)
transformations.
Platelet and WBC counts in whole blood and both
PRP preparations were evaluated through a one-way
analysis of variance (ANOVA), followed by a Tukey test.
PDGF-BB, TGF-β1, TNF-α, IL-4, IL-1ra and HA con-
centrations from both PRG supernatants and synovial
fluid were evaluated in a similar fashion to blood
cells. PDGF-BB, TGF-β1, TNF-α, IL-4, IL-1ra and HAconcentrations in culture media obtained at 48 and
96h from LPS-challenged non-challenged SME groups
cultured with 25 and 50 % P-PRG and L-PRG superna-
tants, respectively, were evaluated using a generalized
lineal model (GLM), followed by a Tukey test when
necessary.
The initial PDGF-BB, TGF-β1, TNF-α, IL-4, IL-1ra and
HA concentrations in fresh culture media with PRG su-
pernatants at 1 and 48h were also considered in the ana-
lysis. However, data regarding the PDGF-BB, TGF-β1,
TNF-α, IL-4, IL-1ra and HA concentrations obtained at
these two periods were compared with the concentra-
tions of these proteins and HA at 48 and 96h, respect-
ively, using a t-paired test. A correlation analysis was
performed in order to determine the Pearson correlation
product (r) between the variables evaluated in the study.
A p-value < 0.05 was accepted as statistically significant
for all tests. Data are presented as mean ±mean standard
error (m.s.e).
Results
Cell concentration in L-PRP and P-PRP
Platelet counts were significantly different between
whole blood, L-PRP and P-PRP, with P-PRP having the
lowest concentration (×0.8), followed by whole blood
(×1) and L-PRP (×2.5). WBC counts were also signifi-
cantly different between the groups evaluated, with L-
PRP having the highest concentration (×4), followed by
whole blood (×1) and P-PRP (×0.15) (Table 1).
Table 1 Concentrations of the cells and molecules evaluated in whole blood, both platelet rich gel (PRG) supernatants and
synovial fluida
Fluid
Variable Whole blood L-PRG P-PRG Synovial fluid
Platelet ×103/μL 124.7 ± 3.1 311.6 ± 20.4b 99.4 ± 4.3c ND
WBC ×103/μL 8.4 ± 3.6 34.2 ± 3.7b 0.13 ± 0.03c ND
RBC ×106//μL 6.31 ± 0.3 1.6 ± 0.4b 0.02 ± 0.01c ND
TGF-β1 (pg/mL) ND 1669.2 ± 313.2 1369.2 ± 21.4 1413.8 ± 4.8
PDGF-BB (pg/mL) ND 3069. 9 ± 1261.6 383.8 ± 80.9b 60.5 ± 0.9b
TNF-α (pg/mL) ND 60 ± 0.5b,c 59 ± 1.4b 66.7 ± 3.3c
IL-4 (pg/mL) ND 75.7 ± 9.3b 61.1 ± 1.52b 101.8 ± 33.7c
IL-1ra (pg/mL) ND 160.4 ± 68.0 58.7 ± 3.1b 77.8 ± 10.7
Hyaluronic acid (ng/mL) ND 6.9 ± 2.9 2.3 ± 1.08 53017.6 ± 12140b
a Data are presented as means (m.s.e).b-c Lowercase letters denote significant differences (p < 0.01) between groups in the same row by Tukey test. ND: no determined
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L-PRP/L-PRG, P-PRP/P-PRG, synovial fluid and culture
media of SME
TGF-β1
TGF-β1 concentration was similar between L-PRG, P-
PRG and synovial fluid (Table 1). The concentration of
TGF-β1 increased over time in each of the groups evalu-
ated, even in the control groups (either with or without
LPS). TGF-β1 concentrations were significantly higher
(p < 0.01) in culture media produced from SME cultured
with 50 % P-PRG supernatant than they were in media
produced from SME cultured with 25 % P-PRG super-
natant. However, no other significant differences were
observed at the commencement of the experiment (1h)
or at the second culture media change (49h) (Fig. 2a-b).
At 48h, the TGF-β1 concentration in all SME groups
increased significantly (p < 0.01) in comparison to that
recorded at the start of the experiment (1h). The
TGF-β1 concentration was significantly (p < 0.01) higher
in the SME group with 50 % L-PRG supernatant as com-
pared to the SME control group without LPS, SME cul-
tured with 25 % L-PRG and 25 % P-PRG supernatants.
The SME cultured with 25 % P-PRG supernatant pre-
sented with a significantly lower (p < 0.01) concentration
of TGF-β1 as compared to all PRG supernatant treated
groups and synovial fluid. The TGF-β1 concentration was
similar across SME control groups (with and without
LPS) (Fig. 2a).
At 96h, a significant increase (p < 0.01) in the concen-
tration of TGF-β1 was observed in the SME group cul-
tured with 50 % L-PRG supernatant as compared with
SME control groups with and without LPS, and the SME
group cultured with 25 % P-PRG supernatant. It is note-
worthy that at 48 and 96h, the concentration of TGF-β1
in the evaluated SME groups was similar to that of syn-
ovial fluid, the SME control group without LPS being
the exception (Fig. 2b).PDGF-BB
L-PRG presented a significantly (p < 0.01) higher PDGF-
BB concentration than did P-PRG and synovial fluid
(Table 1). PDGF-BB concentrations at 1 and 49h were
significantly higher (p < 0.01) in the SME groups cul-
tured with 50 % L-PRG supernatant than they were in
the other SME groups. At 48h, an important diminution
of PDGF-BB concentration was observed in all SME
groups treated with the PRG supernatants (Fig. 3a-b).
At 48h, the SME group cultured with 50 % L-PRG
supernatant presented with a significantly higher (p < 0.01)
concentration of PDFG-BB than did all other groups eval-
uated (Fig. 3a). At 96h a similar trend in the concentration
of PDGF-BB was observed. Note that PDFG-BB was
produced by the SME without the addition of any PRG
supernatant; moreover, at all times, the concentration of
PDGF-BB remained similar among all of the treated
groups and synovial fluid (Fig. 3b).
TNF-α
Synovial fluid demonstrated the highest (p < 0.01) TNF-α
concentration, whereas low concentrations for this
cytokine were observed in both P-PRG supernatants
(Table 1). The TNF-α concentration was significantly
higher (p < 0.01) at 1 and 49h in the SME groups
cultured with both 50 % PRG supernatants (Fig. 4a-b).
However, the TNF-α concentration in all SME groups,
including those that did not receive any PRG super-
natant, was significantly higher at 48 and 96h than at 1
or 49 h. At 48h, the TNF-α concentration was signifi-
cantly higher (p < 0.01) in the SME groups cultured with
50 % PRG supernatants than in either the control groups
or SME groups cultured with both 25 % PRG superna-
tants (Fig. 4a). At 96h, the TNF-α concentration was sig-
nificantly lower in both SME control groups than it was
in both concentrations of L-PRG supernatants and the
50 % P-PRG supernatant. TNF-α concentrations were
Fig. 3 PDGF-BB concentrations obtained in culture media of the synovial membrane explant groups at 48 (a) and 96 h (b). a-b Lowercase letters
denote significant (p < 0.01) differences between groups in the same column by Tukey test. a Significantly different with a: P-PRG 25 % + LPS.
b: L-PRG 50 % + LPS and P-PRG 50 % + LPS. c: L-PRG 50 % + LPS. b Significantly different with a: P-PRG 25 % + LPS. b: L-PRG 50 % + LPS and P-PRG
50 % + LPS. c: SD from L-PRG 50 % + LPS. d: P-PRG 25 % + LPS. e: P-PRG 50 % + LPS. *Denote significant differences (p < 0.01) between the same
variable at 1 h and 48 h and at 49 h and 96 by t-paired test. Data are presented as means (m.s.e)
Fig. 4 TNF-α concentrations obtained in culture media of the synovial membrane explant groups at 48 (a) and 96 h (b). a-b Lowercase letters
denote significant (p < 0.01) differences between groups in the same column by Tukey test. a Significantly different with a: L-PRG 50 % + LPS and
P-PRG 50 % + LPS. b: L-PRG 50 % + LPS and P-PRG 50 % + LPS. c: P-PRG 25 % + LPS. b Significantly different with a: L-PRG 50 % + LPS and P-PRG
50 %+ LPS. b: L-PRG 50 %+ LPS, P-PRG 25 %+ LPS and P-PRG 50 %+ LPS. c: L-PRG 50 %+ LPS and P-PRG 50 %+ LPS. d: P-PRG 25 %+ LPS. e: P-PRG
50 %+ LPS. *Denote significant differences (p < 0.01) between the same variable at 1 h and 48 h and at 49 h and 96 by t-paired test. Data are presented
as means (m.s.e)
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PRG supernatants and synovial fluid at 48 and 96h
(Fig. 4b).
IL-4
Synovial fluid demonstrated the highest (p < 0.01) IL-4
concentration, whereas low concentrations for this
cytokine were observed in both P-PRG supernatants
(Table 1). At 1 and 49h, the IL-4 concentration was sig-
nificantly higher (p < 0.01) in the culture media of the
SME groups cultured with the 50 % PRG supernatants
than it was in those cultured with the 25 % PRG super-
natants (Fig. 5a-b). At 48h, the IL-4 concentration was
significantly higher (p < 0.01) in the culture media of the
SME groups treated with either 25 % or 50 % L-PRG su-
pernatants as compared to the SME group treated with
the 25 % P-PRG supernatant. At this time, the SME
control group without LPS exhibited a significantly
lower (p < 0.01) concentration of IL-4 as compared to
the SME group treated with the 25 % L-PRG super-
natant (Fig. 5a). At 96h a marked drop in the IL-4 con-
centration was observed in the SME control group with
LPS as compared to the SME control group without LPS
and the SME groups treated with both 50 % L-PRG and
P-PRG supernatants. At 48 and 96h, the concentration
of IL-4 was significantly higher (p < 0.01) in synovial
fluid than in the evaluated groups, with the exception of
the SME treated with the 50 % P-PRG supernatant. TheFig. 5 IL-4 concentrations obtained in culture media of the synovial memb
denote significant (p < 0.01) differences between groups in the same colum
b: P-PRG 25 % + LPS. c: P-PRG 50 % + LPS. d: L-PRG 25 % + LPS. e: P-PRG 25
25 % + LPS. c: P-PRG 50 % + LPS. d: Control group + LPS, L-PRG 50 % + LPS
P-PRG 50 % + LPS. f: P-PRG 25 % + LPS and P-PRG 50 % + LPS. g: SD from P
the same variable at 1 h and 48 h and at 49 h and 96 by t-paired test. DatIL-4 concentration in the SME treated with 50 % P-PRG
supernatant was similar to that found in the synovial
fluid (Fig. 5b).
IL-1ra
L-PRG supernatants and synovial fluid presented sig-
nificantly higher (p < 0.01) IL-1ra concentrations than
P-PRG supernatants did (Table 1). Temporally, the
IL-1ra concentration remained consistently and sig-
nificantly higher (p < 0.01) in the SME group treated
with 25 % L-PRG supernatant as compared to all
other experimental groups, synovial fluid and P-PRG
supernatants. IL-1ra increased 10 to 30 times more
in the SME group than in any other group. Interest-
ingly, treating the SME group with 50 % L-PRG
inhibited the production of IL-1ra (Fig. 6a-b).
HA
HA concentration was significantly (p < 0.01) higher in
synovial fluid than both PRG supernatants (Table 1). At
1 and 49h, the HA concentration was significantly lower
(p < 0.01) in the culture media of all SME groups treated
with PRG supernatants. At 48h, there was a significant
increase (p < 0.01) in the concentration of HA in the
SME control group with LPS and the SME group treated
with 25 % L-PRG supernatant as compared to the SME
control group without LPS and the SME groups treated
with other PRG supernatants. At 96h, a significantrane explant groups at 48 (a) and 96 h (b). a-b Lowercase letters
n by Tukey test. a Significantly different with a: a: L-PRG 50 % + LPS.
% + LPS. b Significantly different with a: L-PRG 50 % + LPS. b: P-PRG
and P-PRG 50 % + LPS. e: L-PRG 50 % + LPS, P-PRG 25 % + LPS and
-PRG 50 % + LPS. *Denote significant differences (p < 0.01) between
a are presented as means (m.s.e)
Fig. 6 IL-1ra concentrations obtained in culture media of the synovial membrane explant groups at 48 (a) and 96 h (b). a-b Lowercase letters
denote significant (p < 0.01) differences between groups in the same column by Tukey test. a Significantly different with a: all groups. b: all
groups. b Significantly different with a: all groups. *Denote significant differences (p < 0.01) between the same variable at 1 h and 48 h and at
49 h and 96 by t-paired test. Data are presented as means (m.s.e)
Fig. 7 HA concentrations obtained in culture media of the synovial
membrane explant groups at 48 and 96 h. a-b Lowercase letters denote
significant (p < 0.01) differences between groups in the same column
by Tukey test. Significantly different with a: Control group + LPS and
L-PRG 25 % + LPS. b: L-PRG 50 % + LPS, P-PRG 25 % + LPS and
P-PRG 50 % + LPS. c: L-PRG 50 % + LPS, P-PRG 25 %+ LPS and
P-PRG 50 %+ LPS. d: Control group + LPS and L-PRG 25 % + LPS. e:
P-PRG 25 % + LPS and P-PRG 50 % + LPS. f: P-PRG 50 % + LPS.
*Denote significant differences (p < 0.01) between the same variable
at 1h and 48 h and at 49 h and 96 by t-paired test. Data are presented
as means (m.s.e)
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both the SME control group with LPS and those treated
with 25 % L-PRG supernatant as compared to the SME
control group without LPS. However, the HA concentra-
tion was similar for the SME control group without LPS
and the SME groups treated with 50 % L-PRG supernatant
and with 25 and 50 % P-PRG supernatants; however, in this
last group, the HA concentration was apparently higher
than in the SME group cultured with 50 % L-PRG super-
natant. In contrast, the concentration of HA was signifi-
cantly higher (p < 0.01) in synovial fluid than it was in all
other SME groups at any time (Fig. 7).
Correlations
At 48h, TGF-β1 and PDGF-BB (r = 0.69, p = 0.0001), and
IL-1ra and HA (r = 0.76, p = 0.0001), were found to be sig-
nificantly correlated. Moreover, at 96h, TGF-β1 and PDGF-
BB (r = 0.69, p = 0.0001), PDGF-BB and TNF-α (r = 0.71,
p = 0.0001), PDGF-BB and IL-4 (r = 0.67, p = 0.0001), and
TNF-α and IL-4 (r = 0.81, p = 0.0001) were found to be
significantly correlated.
Discussion
This study investigated the in vitro effects of two
concentrations (25 and 50 %) of L-PRG and P-PRG
Ríos et al. BMC Musculoskeletal Disorders  (2015) 16:153 Page 9 of 12supernatants on SME conditioned with LPS. The results
indicate that both L-PRP and P-PRP supernatants exert
an anti-inflammatory (or regulatory) and anabolic mech-
anism in an in vitro LPS-induced synovial membrane
inflammation.
The molecules evaluated in this study were selected
because they have been implicated in the pathophysi-
ology of OA [19]. TGF-β1 and PDGF-BB were assayed
because they have demonstrated an important anabolic/
anti-inflammatory action on synovial membrane and
cartilage [33]. Both GF increase the production of cartil-
age extracellular matrix (ECM) proteins, decrease both
joint pain and inflammation and promote the differenti-
ation of synovial membrane cells in chondrocytes [19,
33]. Both proteins are stored mainly in platelet alpha
granules. For, this reason, many of the therapeutic effects
of PRP have been attributed to these proteins [5].
TNF-α was selected as a pro-inflammatory cytokine
because this protein and IL-1 represent some of the key
cytokines associated with the catabolic state found in
OA [34]. TNF-α is implicated in synovitis, and its up-
regulation in synovial tissue is associated with a more
aggressive clinical picture of erosive arthritis [35]. Fur-
thermore, a clinical study revealed that this cytokine is a
more useful biomarker for discriminating OA severity in
horses than is IL-1 [36].
IL-1ra and IL-4 were selected because they have an
important anti-inflammatory effect and because they are
up-regulated in OA patients [37, 38]. IL-1ra is a natural
antagonist of IL-1 effects because it blocks the cellular
receptors necessary for inducing joint inflammation and
cartilage catabolism mediated by this last cytokine [39].
IL-4 is associated with chondroprotection because it in-
creases the synthesis of cartilage ECM [40]. This protein
is more anti-inflammatory than anabolic because it
increases the synthesis of IL-1ra and down-regulates
TNF-α [41].
We decided to measure the concentration of these
molecules in synovial fluid to determine which of the
two concentrations of the PRG supernatants could re-
flect a near or similar apparently healthy molecular syn-
ovial fluid environment in the culture media of the SME
groups challenged with LPS. Notably, both PRG super-
natants induced concentrations of GF, cytokine and HA
very similar to those found in synovial fluid when
compared with the SME control groups (either with
LPS or without LPS). However, every PRG supernatant
and its respective concentration produced different
synovial membrane responses in the molecules evalu-
ated in the study, which could indicate that different
mechanisms of action underlie the anti-inflammatory
and anabolic effects depending on the cellular and
molecular profile of the PRP/PRG supernatant used in
the study.The two most attractive PRG supernatants and con-
centrations for exploring the in vivo effects of these sub-
stances, whether in an animal model of OA or in the
clinical setting, were 25 % L-PRG and 50 % P-PRG su-
pernatants. At a concentration of 25 %, the L-PRG
supernatant produced the highest IL-1ra concentration
in the culture media from SME when compared with the
rest of the SME groups treated with both PRG at differ-
ent concentrations. IL-1ra has been evaluated experi-
mentally and clinically as a treatment for OA on the
basis of its capacity to inhibit the binding of both IL-1α
and IL-1β to their active receptor [42]. However, there
are contradictory results from clinical trials, in which
this purified protein had little success, probably because
there was sufficient IL-1ra already in the OA synovial
fluid or simply because IL-1ra did not work well in OA
in the context of an inflammatory milieu [43].
Furthermore, the 25 % L-PRG supernatant produced
an extensive depression in HA synthesis in the SME at
96h. This intriguing situation could be explained by way
of an inhibitory mechanism in HA production as medi-
ated by a higher concentration of IL-1ra. However, to
our knowledge, this mechanism has not been previously
reported, although it is known that IL-1ra does not
affect HA synthesis in fibroblasts in vitro [44]. Moreover,
it is important to consider that patients with cranial
cruciate knee injury who were treated with IL-1ra
(anakinra) demonstrated better clinical outcomes and a
significant decrease in plasma HA than did the placebo
group [45]. However, in vitro research has demonstrated
that IL-1ra prevents cartilage ECM explant degradation
[46]. Our results, in conjunction with the aforemen-
tioned study, could indicate that IL-1ra, or associated
therapies such as IRAP or autologous conditioned
serum, can provide relief from joint inflammation after
injury, but does not induce joint anabolism [47].
The elevated and sustained concentration of IL-4 over
time in the 50 % P-PRG supernatant indicated an anti-
inflammatory profile. IL-4 is an anti-inflammatory cyto-
kine associated with the downregulation of IL-1β and
matrix metalloproteinases 2, 9 and 13 in SME [48]. In
addition, HA production was sustained in response to
the 50 % P-PRG supernatant, but depressed in both the
SME control group with LPS and the SME group cul-
tured with 25 % L-PRG supernatant. This desirable ana-
bolic effect, observed in the 50 % P-PRG supernatant,
has been observed previously in vitro, in which synovio-
cytes from OA patients were cultured with P-PRP [15].
Both platelet TGF-β1 and PDGF-BB have been shown to
induce the synthesis of HA through the up-regulation of
HA synthase isoform 2 [49].
Although a statistical correlation does not always
imply a direct biological interaction, we observed im-
portant correlations that could potentially be useful for
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tions observed in this in vitro system of synovial inflam-
mation and the biological responses of the SME
challenged with LPS to the PRG supernatants. The cor-
relation observed between TGF-β1 and PDGF-BB is ex-
plained by way of GF being stored and released from
PLT in PRP [28]. The strong correlation (0.76) between
IL-1ra and HA at 48h suggests that a molecular mech-
anism, mediated by IL-1ra, induced strong HA produc-
tion in the first 48h, but that this cytokine might also be
implicated in a later HA production inhibitory mechan-
ism. This metabolic change was most pronounced in
the culture media of the SME groups cultured with 25 %
L-PRG supernatant at 96h.
Other important and possibly chained biological corre-
lations were observed at 96h between PDGF-BB and
TNF-α, PDGF-BB and IL-4, and TNF-α and IL-4. These
correlations could indicate the importance of PDGF-BB
in the production or up-regulation of the anti-
inflammatory cytokine IL-4. On the other hand, the re-
sults from this study demonstrate that at least in this
in vitro system of synovial membrane inflammation,
TNF-α may act more like a regulatory than a pro-
inflammatory cytokine [50]. This finding could be con-
troversial, given the results observed in animal models
and in patients with natural synovial inflammatory
diseases. In such cases, the increased concentration or
up-regulation of TNF-α correlates with the severity of
the synovial membrane inflammation and, consequently
with articular cartilage degradation [36, 46, 51].
The results of this study support the hypothesis that
some PRP preparations could be indicated for the treat-
ment of patients with OA. It is also important to note
that the higher concentration of PLTs in PRP is not cru-
cial, as previously indicated by Weibrich et al. [52]. Our
results support the findings of several previous tendon
explant studies by demonstrating that in order to induce
anabolic signalling, it is more important to reduce the
WBC concentrations than it is to increase the PLT con-
centration in PRP [24, 25].
The present study had several limitations, mainly asso-
ciated with the fact that animal models of joint disease
are better than in vitro studies in capturing the bio-
logical phenomena in patients with naturally occurring
OA or inflammatory synovitis. As mentioned by Andia
and Maffulli [53], the current in vitro systems of joint
disease are not able to address the role of the immuno-
logic system, notably the macrophage activity induced by
proteins of the group-specific component globulin that
activates these cells via the innate immune toll-like re-
ceptor 4 and induces the expression of TNF-α, IL-1β,
IL-6, and vascular endothelial growth factor. Therefore,
in vitro studies are not fully able to reflect the real
in vivo joint disease and its response to treatments [53].On the other hand, we used the blood of a single animal
for culturing the SME of different horses; this situation
is not ideal in clinical conditions, but it is advantageous
in in vitro studies because the cellular product evaluated
can be standardized for cell and protein concentrations,
which reduces the variability in the biological response
of the tissues treated experimentally. Finally, many GF
and cytokines implicated in the genesis of OA, mainly
IL-1 and IL-6 [37], were not measured in this study;
thus, it is not possible to describe the actual effect of
PRP on these proteins and their interaction with the
molecules evaluated.
Conclusions
The results of this study lead to the conclusion that both
L-PRG and P-PRG supernatants at different concentra-
tions produce various inflammatory, anti-inflammatory
and anabolic responses in SME conditioned with LPS,
which confirmed the working hypothesis. Although the
25 % L-PRG supernatant induced the highest concentra-
tion of IL-1ra in the culture media from the SME condi-
tioned with LPS at 48 and 96h, it produced a strong
metabolic depression in the production of HA at 96h. In
contrast, the 50 % P-PRG supernatant produced a more
sustained concentration of IL-4 and a significant in-
crease in the production of HA during that period of
time. These in vitro findings suggest that the anabolic
and anti-inflammatory joint responses will depend on the
leukocyte and platelet concentration of the PRP prepar-
ation and on the volume of this substance injected. More-
over, it is possible that leukoreduced PRP preparations are
more effective in the medical treatment of patients with
OA and inflammatory synovitis. However, additional
in vivo studies, evaluating the effect of both L-PRP and
P-PRP in either animal models or in patients are necessary.
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